AZD9291

AZD9291

AZD9291

• January 13, 2016
• Read time: 1 minute

Phase 1 clinical trial information in Japan for non-small cell lung cancer patients studying AZD9291 (osimertinib), c-MET inhibitors, and MEK inhibitors. Separate Phase 1 clinical trials are evaluating safety of durvalumab, volitinib, and selumentinib combined with osimertinib. AZD9291 (osimertinib)

Volunteer Eligibility Criteria

1. Age 20 years or older

2. Diagnosed with non-small cell lung cancer

3. Confirmed EGFR gene mutation

4. Continuous disease progression despite EGFR TKI treatment

5. At least one measurable lesion

6. PS 0 or 1

Exclusion Criteria

1. Prior use of PD-1, PD-L1, AZD6094 or c-MET inhibitors, AZD6244 or MEK, RAS or RAF inhibitors.

2. Spinal metastasis or spinal cord compression.

3. Serious systemic disease, inflammation, or other conditions unsuitable for clinical trials.

Clinical trial period: August 2014 to June 2017. For related clinical trial information, please refer to the link below. Application procedures and implementation locations are based on the linked information. This article is provided for reference only.

https://clinicaltrials.gov/ct2/show/NCT02143466?term=NCT02143466&rank=1

#Lung Cancer

• Clinical Trial Medications

  (Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase II Clinical Trial Results. (Lung Cancer) Is Enhertu Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody DS-7300 Effective?

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4